Here are the studies that match your search criteria. If you are interested in participating, please reach out to the contact listed for the study. If no contact is listed, contact us and we'll help you find the right person.
1
Study Matches
Site for Phase 1b, Open-label Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, Immunogenicity, and Antitumor Activity of
MEDI5752 in Combination with Axitinib in Subjects with
Advanced Renal Cell Carcinoma
Determine the maximum tolerated dose or maximum administered dose of MEDI5752 combined with axitinib
Assess the safety and tolerability of MEDI5752 combined with axitinib
Assess the antitumor activity of MEDI5752 combined with axitinib
Body weight > 35 kg Histologically or cytologically proven advanced RCC Advanced RCC not previously treated in that setting Must have at least 1 measurable lesion according to RECIST v1.1 Life expectancy ≥ 12 weeks
Exclusion Criteria:
Previous treatment with axitinib Previous treatment with mTOR inhibitors, PD-1, PD-L1, or CTLA-4 inhibitors for RCC History of active primary immunodeficiency History of organ transplant